

# Tuberculosis profile: Kenya

Population 2019: 53 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	140 000 (86 000-208 000)	267 (163-396)
HIV-positive TB incidence	37 000 (22 000-54 000)	70 (43-104)
MDR/RR-TB incidence**	2 200 (950-3 900)	4.1 (1.8-7.4)
HIV-negative TB mortality	20 000 (11 000-30 000)	37 (21-58)
HIV-positive TB mortality	13 000 (7 800-19 000)	24 (15-36)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	1.3% (0.74-2)
Previously treated cases	4.6% (4-5.4)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	60% (41-98)
TB patients facing catastrophic total costs, 2017	27% (21-32)
TB case fatality ratio (estimated mortality/estimated incidence), 2019	24% (13-38)

## TB case notifications, 2019

Total new and relapse	84 345
- % tested with rapid diagnostics at time of diagnosis	63%
- % with known HIV status	98%
- % pulmonary	86%
- % bacteriologically confirmed ^	64%
- % children aged 0-14 years	10%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	31%
- % men	59%
Total cases notified	86 385

### TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	21 564	26%
- on antiretroviral therapy	20 877	97%

### Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	76%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	86%
Laboratory-confirmed cases - MDR/RR-TB ^^	507
Patients started on treatment - MDR/RR-TB ^^	692
Laboratory-confirmed cases - XDR-TB ^^	1
Patients started on treatment - XDR-TB ^^	1
MDR/RR-TB cases tested for resistance to any fluoroquinolone	151

### Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	84%	94 534
Previously treated cases, excluding relapse, registered in 2018	72%	1 935
HIV-positive TB cases registered in 2018	79%	24 521
MDR/RR-TB cases started on second-line treatment in 2017	70%	390
XDR-TB cases started on second-line treatment in 2017	0%	1

### TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	82%
---	-----



### Treatment success rate



### Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	39% (35-42)
---	----------------

## TB financing

National TB budget, 2020 (US\$ millions)	75
- Funding source, domestic	24%
- Funding source, international	25%
- unfunded	51%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

---

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)